Regulatory milestones

Algeta ASA (OSE:ALGETA) gained NOK5.10 to NOK183.90 last week after partner Bayer AG (Xetra:BAYN) said FDA accepted and granted Priority Review to an NDA for radium-223 dichloride (formerly Alpharadin) to treat castration-resistant prostate cancer (CRPC) in patients with bone metastases. An eight-month Priority Review would place the PDUFA date in August; the specific date is not disclosed. Bayer submitted an MAA to EMA in December.